# Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer

> **NCT05671822** · PHASE2 · RECRUITING · sponsor: **Suzhou Suncadia Biopharmaceuticals Co., Ltd.** · enrollment: 258 (estimated)

## Conditions studied

- HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** SHR-A1811 and SHR-1701
- **DRUG:** SHR-A1811 and capecitabine
- **DRUG:** SHR-A181, SHR-1701, and capecitabine
- **DRUG:** SHR-A1811, SHR-1316, and capecitabine
- **DRUG:** SHR-A1811, SHR-1316, capecitabine,and oxaliplatin
- **DRUG:** SHR-A1811, SHR-1316, and 5-FU
- **DRUG:** SHR-A1811, SHR-1316, and capecitabine
- **DRUG:** SHR-1316 and SHR-A1811
- **DRUG:** SHR-A1811 and capecitabine
- **DRUG:** SHR-A1811, SHR-1316, and 5-FU
- **DRUG:** SHR-A1811and 5-FU
- **DRUG:** SHR-A1811, SHR-1316, capecitabine,and oxaliplatin

## Key facts

- **NCT ID:** NCT05671822
- **Lead sponsor:** Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-14
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 258 (ESTIMATED)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05671822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05671822, "Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05671822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*